SAN DIEGO, December 1, 2015 /PRNewswire/ – ProSciento Inc., a clinical research organization (CRO) focused on diabetes, obesity and NAFLD/NASH, announced today the addition of Christian Weyer, M.D., M.A.S. to its executive management team as President and Chief Development Officer. Dr. Weyer was most recently President and CEO of Fate Therapeutics. Prior to that he held a number of senior leadership positions at Amylin Pharmaceuticals where he contributed to the development and approval of several first-in-class medicines for diabetes and lipodystrophy, while also leading the company’s programs and global strategic partnership in obesity. Dr. Marcus Hompesch will continue to lead ProSciento as the company’s CEO and Chairman of the Board.
Dr. Weyer’s career in metabolic drug development spans more than 20 years, involving clinical studies and regulatory submissions at all stages of product development and across the continuum of diabetes, obesity and NAFLD/NASH. In the newly created role of Chief Development Officer, Dr. Weyer will oversee the company’s clinical development services and forge new strategic partnerships with biopharmaceutical companies and other stakeholder groups pursuing clinical development programs or licensing opportunities for metabolic drug or device candidates.
“Building upon its long-standing scientific reputation, therapeutic focus, track record of clinical trial execution, and growing network of metabolic research partners, ProSciento is uniquely positioned to further expand its global leadership as the partner of choice for metabolic R&D,” said Dr. Weyer. “I’m excited to join the Company during this next stage of strategic expansion, as we work to offer clients worldwide an unrivaled and comprehensive suite of clinical research and development services to enable efficient and expeditious paths to value creation.”
“We are excited to welcome Chris to our leadership team during this time of dynamic growth,” said Dr. Hompesch. “Chris’ career leading drug development programs and global pharmaceutical partnerships, in addition to his deep scientific expertise in metabolic research, makes him an ideal addition to the leadership team at ProSciento. Chris will be instrumental as we expand our clinical development consulting services for clients seeking a science-driven, therapeutically focused CRO with a proven track record of facilitating clinical, regulatory and licensing strategies.”
Dr. Weyer is globally recognized as an accomplished business leader with scientific expertise in diabetes and obesity through his work in academia, government research, and the biopharmaceutical settings. Following training at the Department of Metabolic Disorders, World Health Organization Collaborating Center for Diabetes Treatment and Prevention, at the University of Düsseldorf, Germany, Dr. Weyer worked at the National Institutes of Health, NIDDK, conducting clinical research on the pathogenesis of obesity and type 2 diabetes. During his subsequent 12-year tenure with Amylin Pharmaceuticals, he held a number of senior leadership positions in R&D and corporate development, serving most recently as Senior Vice President of R&D. Following Amylin’s acquisition by Bristol-Myers Squibb in August 2012, he joined Fate Therapeutics as President and CEO, where he steered the company’s transition into a publicly-traded cellular therapeutics company, advancing new programs and partnerships in immuno-oncology, inherited metabolic disorders and type 1 diabetes.
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
For business development inquires:
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427